[
  {
    "ts": null,
    "headline": "RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test",
    "summary": "Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.",
    "url": "https://finnhub.io/api/news?id=138c00c2b653a620221cbac32ac6cca9759d4b83fb03c135a17331e28d30480b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736780040,
      "headline": "RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test",
      "id": 132500831,
      "image": "https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.",
      "url": "https://finnhub.io/api/news?id=138c00c2b653a620221cbac32ac6cca9759d4b83fb03c135a17331e28d30480b"
    }
  },
  {
    "ts": null,
    "headline": "Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing",
    "summary": "WALTHAM, Mass. & SAN DIEGO, January 13, 2025--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and stren",
    "url": "https://finnhub.io/api/news?id=498b46d30a3757c2867482cb708f398881f660268f344e2e6c4a9370ea284e47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736773200,
      "headline": "Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing",
      "id": 132500832,
      "image": "https://media.zenfs.com/en/business-wire.com/4b135df3b22403b9a3d37f080bce70e2",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass. & SAN DIEGO, January 13, 2025--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and stren",
      "url": "https://finnhub.io/api/news?id=498b46d30a3757c2867482cb708f398881f660268f344e2e6c4a9370ea284e47"
    }
  }
]